Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Modern CVD management webinar series || #2 of 3 || Case-based expert discussion
About This Webinar
Join us live, as EAS President Prof Kausik Ray, UK, and the experts taking part in this webinar - Prof Lale Tokgozoglu (Turkey) & Prof Frederick Raal (South Africa) present and discuss cases including including ACS patient with comorbidities, and a late-diagnosis HeFH patient.
As part of the EAS programme "Improving the Cardiovascular Health of the Population - everything the modern Clinician needs to know" this webinar is the second in a series of three interactive live webinars.
Throughout the series, expert physicians from EAS will use their experience of difficult cases to illustrate how to implement current guidelines and put into practice relevant theoretical knowledge, talking us through how they assess and manage diverse CVD cases.
-----------
EAS have independently organised all matters related to this activity, including content and presenters. We acknowledge financial support, in the form of an educational grant, received from Amgen in support of the programme.
Agenda
- Interactive case presentations by Prof Lale Tokgozoglu
- Interactive case presentations by Prof Frederick Raal
- Moderated discussion and audience Q&A
Who can view: Everyone
Webinar Price: Free
Featured Presenters
Prof
S. Lale Tokgözoğlu graduated from the Hacettepe University Faculty of Medicine in 1982.
Active in EAS in various roles over many years, she is the current past-President of EAS, and was the President of the 77th EAS Congress in İstanbul. She also served as the president of the ‘Atherosclerosis and Vascular Biology Working Group of the ESC’ between 2008 and 2010. She has served on the boards of the ESC and IAS Committees, and the Prevention Association of ESC. as Member-at-Large. She has been serving on the Scientific Program Committee of ESC since 1995. She has been a member of the young investigator award committees of the IAS.
Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014.
Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and as Vice President between 2008 and 2010 and the President of the Turkish Society of Cardiology between 2014-2016. She was the first female President of this society in its history of 52 years. She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey. She has been on the Guideline Committee for the Prevention of Coronary Heart Disease in Turkey in 1995 and in 2002 when the Guidelines were revised.
Prof Tokgözoğlu has more than 400 publications, has authored 3 books and several book chapters. Prof. Tokgözoğlu is on the Editorial Board for European Heart Journal, Atherosclerosis, Anatolian Journal of Cardiology and Archives of the Turkish Society of Cardiology. Prof. Tokgözoğlu is the Fellow of the American College of Cardiology (FACC) and the European Society of Cardiology (FESC). Prof. Tokgözoğlu has been an author on the EAS/ESC dyslipidemia guidelines in 2011, 2016 & 2019.
Active in EAS in various roles over many years, she is the current past-President of EAS, and was the President of the 77th EAS Congress in İstanbul. She also served as the president of the ‘Atherosclerosis and Vascular Biology Working Group of the ESC’ between 2008 and 2010. She has served on the boards of the ESC and IAS Committees, and the Prevention Association of ESC. as Member-at-Large. She has been serving on the Scientific Program Committee of ESC since 1995. She has been a member of the young investigator award committees of the IAS.
Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014.
Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and as Vice President between 2008 and 2010 and the President of the Turkish Society of Cardiology between 2014-2016. She was the first female President of this society in its history of 52 years. She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey. She has been on the Guideline Committee for the Prevention of Coronary Heart Disease in Turkey in 1995 and in 2002 when the Guidelines were revised.
Prof Tokgözoğlu has more than 400 publications, has authored 3 books and several book chapters. Prof. Tokgözoğlu is on the Editorial Board for European Heart Journal, Atherosclerosis, Anatolian Journal of Cardiology and Archives of the Turkish Society of Cardiology. Prof. Tokgözoğlu is the Fellow of the American College of Cardiology (FACC) and the European Society of Cardiology (FESC). Prof. Tokgözoğlu has been an author on the EAS/ESC dyslipidemia guidelines in 2011, 2016 & 2019.
Prof
MBBCh, FRCP, FCP(SA), Cert Endo, MMED, PhD
Head, Division of Endocrinology & Metabolism
Director, Carbohydrate and Lipid Metabolism Research Unit Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Professor Raal is currently Professor and Head of the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
He has authored or co-authored over 300 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis. He is on the Editorial Board of Atherosclerosis and is a Board member of the International Atherosclerosis Society.
Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). His Unit has one of the largest cohorts, if not the largest cohort, of homozygous FH patients in the world and has contributed and continues to contribute to the management of these patients. The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.
Head, Division of Endocrinology & Metabolism
Director, Carbohydrate and Lipid Metabolism Research Unit Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Professor Raal is currently Professor and Head of the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
He has authored or co-authored over 300 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis. He is on the Editorial Board of Atherosclerosis and is a Board member of the International Atherosclerosis Society.
Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). His Unit has one of the largest cohorts, if not the largest cohort, of homozygous FH patients in the world and has contributed and continues to contribute to the management of these patients. The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.
Professor
BSc(hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA
Kausik Ray is Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Diseas Prevention and the Deputy Director of the Imperial Clinical Trial Unit, Imperial College London and a Consultant Cardiologist.
Professor Ray received his medical education (MBChB) at the University of Birmingham, his MD at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and an MPhil in epidemiology from the University of Cambridge.
Professor Ray’s research interests focus on preventing the global consequences of atherosclerosis through large-scale population studies evaluating the burden of disease and improving risk prediction and through the study of novel therapies in the setting of multi-centre international clinical trials to offer solutions to help prevent death and disability from cardiovascular disease. As such, he is the global PI of several ongoing Cardiovascular trials and registries.
His publications are included in the NEJM, Lancet, JAMA, Circulation, JACC and EHJ amongst others and have received over 54,000 citations (2019 H index of 68, i10 of 159) and in 2018 he was listed by Clarivate Analytics as among the top 1% of authors cited globally in clinical medicine.
The impact of his novel research findings has contributed to current US and European guidelines amongst others.
An active member of the EAS, Professor Ray has contributed to more than 6 EAS Consensus Panel statements, been an invited speaker at the EAS annual congress for several years, was an EAS program committee member for 2015 (Glasgow) and 2017 (Prague) as well as his ongoing contributions to masterclasses and other EAS educational activities. Since 2017 he has served on the EAS Executive committee.
In 2014 he independently initiated and obtained funding for the EAS FH studies collaboration, the first global registry of its kind, now encompassing over 68 countries and approximately 60,000 cases, for which he is the lead.
Prof Ray has worked extensively to extend the EAS mission across Europe, the Asia Pacific, Gulf region and Latin America through education and collaborations.
Kausik Ray is Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Diseas Prevention and the Deputy Director of the Imperial Clinical Trial Unit, Imperial College London and a Consultant Cardiologist.
Professor Ray received his medical education (MBChB) at the University of Birmingham, his MD at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and an MPhil in epidemiology from the University of Cambridge.
Professor Ray’s research interests focus on preventing the global consequences of atherosclerosis through large-scale population studies evaluating the burden of disease and improving risk prediction and through the study of novel therapies in the setting of multi-centre international clinical trials to offer solutions to help prevent death and disability from cardiovascular disease. As such, he is the global PI of several ongoing Cardiovascular trials and registries.
His publications are included in the NEJM, Lancet, JAMA, Circulation, JACC and EHJ amongst others and have received over 54,000 citations (2019 H index of 68, i10 of 159) and in 2018 he was listed by Clarivate Analytics as among the top 1% of authors cited globally in clinical medicine.
The impact of his novel research findings has contributed to current US and European guidelines amongst others.
An active member of the EAS, Professor Ray has contributed to more than 6 EAS Consensus Panel statements, been an invited speaker at the EAS annual congress for several years, was an EAS program committee member for 2015 (Glasgow) and 2017 (Prague) as well as his ongoing contributions to masterclasses and other EAS educational activities. Since 2017 he has served on the EAS Executive committee.
In 2014 he independently initiated and obtained funding for the EAS FH studies collaboration, the first global registry of its kind, now encompassing over 68 countries and approximately 60,000 cases, for which he is the lead.
Prof Ray has worked extensively to extend the EAS mission across Europe, the Asia Pacific, Gulf region and Latin America through education and collaborations.
Hosted By
Attended
(61)
Recommended